Background: The role of fulvestrant in the management of intestinal obstruction associated with lobular carcinoma has not been specifically described.
Case Presentation: Herein we present two cases where fulvestrant, as the only available parenteral endocrine agent for postmenopausal advanced breast cancer has the opportunity to provide a means to initiate treatment in those patients who present with varying degrees of intestinal obstruction.
Conclusion: Fulvestrant may obviate the use of chemotherapy while achieving sustained clinical benefit with less toxicity, in appropriately selected patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613396 | PMC |
| http://dx.doi.org/10.1186/1477-7819-6-128 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bottom up design of nanoparticles for anti-cancer diapeutics: "put the drug in the cancer's food".
J Drug Target
November 2016
b Center for Single Particle Science and Engineering (SPSE) , University of Southern Denmark, Odense , Denmark.
The story starts in Basel at CLINAM in 2013, when I asked Pieter about making nanoparticles and he advised me to "try this solvent-exchange method we have developed for making limit sized particles". We are particularly interested in what are "limit size materials" because we want to test the feasibility of an idea: could we design, make, develop, and test the concept for treating metastatic cancer by, "Putting the Drug in the Cancer's Food? "Limit size" is the size of the cancer's food, ? the common Low Density Lipoprotein, (LDL) ~20 nm diameter. In this contribution to Pieter's LTAA we focus on the "bottom" (nucleation) and the "up" (growth) of "bottom-up design" as it applies to homogeneous nucleation of especially, hydrophobic drugs and the 8 physico-chemical stages and associated parameters that determine the initial size, and any subsequent coarsening, of a nanoparticle suspension.
View Article and Find Full Text PDFFulvestrant - a novel endocrine therapy for breast cancer.
Curr Med Chem
June 2010
University of Nottingham, Nottingham University Hospitals, Nottingham, UK.
Fulvestrant is a novel endocrine therapy for breast cancer, with a unique structure and mode of action. It binds competitively to the oestrogen receptor (ER), with high affinity, and downregulates ER by functional blockade and increased turnover. Fulvestrant has reached the clinic via extensive pre-clinical and clinical trials, which demonstrated fulvestrant's unique characteristics and showed that they translate to equivalent or improved clinical efficacy compared to established endocrine agents.
View Article and Find Full Text PDFThe use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma.
World J Surg Oncol
December 2008
Division of Breast Surgery, University of Nottingham, Nottingham, UK.
Background: The role of fulvestrant in the management of intestinal obstruction associated with lobular carcinoma has not been specifically described.
Case Presentation: Herein we present two cases where fulvestrant, as the only available parenteral endocrine agent for postmenopausal advanced breast cancer has the opportunity to provide a means to initiate treatment in those patients who present with varying degrees of intestinal obstruction.
Conclusion: Fulvestrant may obviate the use of chemotherapy while achieving sustained clinical benefit with less toxicity, in appropriately selected patients.
FDA drug approval summaries: fulvestrant.
Oncologist
February 2003
Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, HFD-150, 5600 Fishers Lane, Rockville, MD 20857, USA.
Patients with hormone-sensitive breast cancer who have responded to tamoxifen may receive additional benefit from a second endocrine agent following progression or relapse after tamoxifen therapy. Fulvestrant (Faslodex((R)), ICI 182780, AstraZeneca Pharmaceuticals; Wilmington, Delaware) is a selective antagonist of estrogen designed to have no estrogenic effects. Lack of aqueous solubility led to the development of a parenteral formulation for monthly intramuscular administration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!